Toxikon Corporation celebrates its 30th year in business. Originally formed as Cambridge Diagnostics in 1977, the company has evolved from a small research and clinical laboratory to a well recognized international life science company. Dedicated to research and development, GLP, and GMP projects, Toxikon serves the pharmaceutical, biotech, and medical device industries, and meets the needs of microbiology, cell cultured-based assays, in vivo assays, and analytical chemistry.
According to CEO Laxman Desai, “the company is proud of its growth and many accomplishments over the years, and looks forward to continued growth and success moving forward. Toxikon is perfectly positioned to take advantage of the growing outsourcing business model in product development. Our staff are seasoned scientific, technical, and support professionals who understand the needs of the industry along this value chain. We are proud of their collective milestone achievements in facilitating our customers goals in bringing new technology to market.”
The company plans on continuing to enhance its capabilities and state-of-the-art instrumentation testing, and to continue to optimize the client experience for fully integrated analytical support services.
